Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – Melanotropin or eledoisin; related peptides
Reexamination Certificate
2005-07-05
2008-03-11
Kam, Chih-Min (Department: 1656)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
Melanotropin or eledoisin; related peptides
C530S317000, C530S321000, C530S300000, C530S328000, C530S329000, C514S009100, C514S011400, C514S012200, C514S015800, C514S016700, C514S018700, C424S009100, C436S811000
Reexamination Certificate
active
07342089
ABSTRACT:
A highly selective melanocortin-4 receptor antagonist cyclic peptide of the formulawhere R1, R2, R3, R4a, R4b, R5, R6, R7, x, y and z are as defined in the specification, and a method of treating body weight disorders, including cachexia, sarcopenia and wasting syndrome or disease, and treating inflammation and immune disorders.
REFERENCES:
patent: 4938763 (1990-07-01), Dunn et al.
patent: 5693608 (1997-12-01), Bechgaard et al.
patent: 5731408 (1998-03-01), Hadley et al.
patent: 5908609 (1999-06-01), Lee et al.
patent: 5908825 (1999-06-01), Fasano et al.
patent: 5977070 (1999-11-01), Piazza et al.
patent: 6054556 (2000-04-01), Huby et al.
patent: 6100048 (2000-08-01), Cone et al.
patent: 6284729 (2001-09-01), Bernfield et al.
patent: 6432438 (2002-08-01), Shukla
patent: 6476187 (2002-11-01), Cone et al.
patent: 6613874 (2003-09-01), Mazur et al.
patent: 6673767 (2004-01-01), Brodbeck et al.
patent: 6693165 (2004-02-01), Bednarek
patent: 6716810 (2004-04-01), Brennan et al.
patent: 2002/0016291 (2002-02-01), Bednarek
patent: 2003/0032791 (2003-02-01), Alan et al.
patent: 2003/0105024 (2003-06-01), Cone et al.
patent: 2003/0113263 (2003-06-01), Marks et al.
patent: WO 03/006620 (2003-01-01), None
Hruby et al. , J. Med. Chem. 38, 3454-3461 (1995).
Huszar D., Lynch C. A., Fairchild-Huntress V., et al. Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell 88:131-141 (1997).
Roubenoff R. The pathophysiology of wasting in the elderly. J. Nutr. 129(1S Suppl.):256S-259S (1999).
Fan W., Boston B. A., Kesterson R.A ., Hruby V. J., Cone R. D. Role of melanocortinergic neurons in feeding and the agouti obesity syndrome. Nature 385:165-168 (1997).
Rossi, M., et al., A C-terminal fragment of Agouti-related protein increases feeding and antagonizes the effect of alpha-melanocyte . . . Endocrinology 139:4428-31 (1998).
Wisse, B.E., et al., Reversal of cancer anorexia by blockade of central melanocortin receptors in rats. Endocrinology 142:3292-3301 (2001).
Marks D. L., Ling N., Cone R. D. Role of the central melancortin system in cachexia. Cancer Research 61:1432-1438 (2001).
Synthetic Peptides: A User's Guide, G. A. Grant, editor, W.H. Freeman & Co., New York (1992)—the teachings of which are incorporated herein by reference, including the text and table set forth at pp. 11 through 24.
Hruby V. J., Al obeidi F., Kazmierski W., Biochem. J. 268:249-262 (1990).
Toniolo C., Int. J. Peptide Protein Res. 35:287-300 (1990).
Barn D.R., Morphy J.R., Rees D.C. Synthesis of an array of amides by aluminum chloride assisted cleavage of resin-bound esters. Tetrahedron Lett. 37, 3213-3216 (1996).
DeGrado W. F. Kaiser E. T. Solid-phase synthesis of protected peptides on a polymer bound oxime: Preparation of segments comprising the sequences of a cytotoxic 26-peptide analogue. J. Org. Chem. 47:3258-3261 (1982).
Catania A. et al., Trends Endocrinol. Metab. 11:304-308 (2000).
Gantz I. and Fong T. M., Am. J. Physiol. Endocrinol. Metab. 284:E468-E474 (2003).
Catania A., Gatti S., Colombo G., Lipton J. M., Pharmacol. Rev. 56:1-29 (2004).
Seeley R.J., Blake K., Rushing P.A. et al. The role of CNS glucagons-like peptide-1 (7-36) amide receptors in mediating the visceral illness effects of lithium chloride.J. Neurosci. 20:1616-1621 (2000).
Galande A. K., Spatola A. F. Lett. Pept. Sci. 8:247 (2002).
Burris Kevin D.
Rajpurohit Ramesh
Shadiack Annette M.
Sharma Shubh D.
Shi Yi-Qun
Kam Chih-Min
Palatin Technologies Inc.
Slusher Stephen A.
LandOfFree
Cyclic peptides for treatment for cachexia does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cyclic peptides for treatment for cachexia, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cyclic peptides for treatment for cachexia will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3967475